Is ALC business exposed to Coronavirus impact?, page-40

I should clarify that my previous comments were general observations and were not specific to Alcidion. Apologies for any confusion.

From my personal perspective, I feel that I have sufficient visibility and, more importantly, confidence in what they meant by recurring. But then this confidence is not extended to figures by some other companies and other individuals may hold a different view.

I started off with a revenue multiple approach to derive an implied valuation for Alcidion because it was simple. I noted the limitations and that it is was not meant to be definitive but rather to provide a starting point to inform the investment decision making process.

As Alcidion continues to evolve and grow, so must how I assess the company both operationally and financially. Things like cost of sales (which admittedly I did not pay a whole lot of attention to pre and just after MKM Health acquisition) and other metrics such as tender and/or revenue pipelines become more important.

Again, there is no right or wrong answer and this is why this forum is generally positive as it provides what is in my view, a safe environment for constructive debate to occur. I sincerely hope this would continue as I have lots more to learn!